Clinical Trial Update: Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 trial of intravitreal LFG316 in geographic atrophy and age-related macular degeneration has completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• LFG316

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Geographic Atrophy, Age-related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2018-07-27